Search - tctmd.com

Displaying 81 - 100 of 142

Sort: Relevancy | Date

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

Patients With Chest Pain Less Likely to Die After Discharge From High-Volume EDs

L.A. McKeown

October 26, 2018

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

High-Sensitivity Troponins May Help Identify Obstructive CAD in Stable, Symptomatic Patients

Yael L. Maxwell

March 30, 2018

News Daily News

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Caitlin E. Cox

March 26, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Daily News

For CHD Patients, Physical Activity More Meaningful Than Weight Changes Over Time

Caitlin E. Cox

March 13, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News ACC 2018

Googling of Cardiac Symptoms Tracks With Hospital Admissions for Coronary Disease

Yael L. Maxwell

March 09, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

Caitlin E. Cox

January 18, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

Routine Coronary CTA to Rule Out ACS in Acute Chest Pain Questioned in ROMICAT-II Subanalysis

L.A. McKeown

November 21, 2017

Advertisement

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Patients With Chest Pain Less Likely to Die After Discharge From High-Volume EDs

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

High-Sensitivity Troponins May Help Identify Obstructive CAD in Stable, Symptomatic Patients

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

For CHD Patients, Physical Activity More Meaningful Than Weight Changes Over Time

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Googling of Cardiac Symptoms Tracks With Hospital Admissions for Coronary Disease

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Routine Coronary CTA to Rule Out ACS in Acute Chest Pain Questioned in ROMICAT-II Subanalysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content